Patents by Inventor Paul J. Maddon
Paul J. Maddon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6342586Abstract: This invention provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention also provides an immunoconjugate which comprises 1) a gamma radiation-emitting radionuclide of low to moderate cytotoxicity and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention further provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a heterotetramer comprising two heavy chains and two light chains, both heavy chains being either 1) IgG2 heavy chains or b) chimeric CD4-IgG2 heavy chains, and both light chains being either a) kappa light chains or b) chimeric CD4-kappa light chains.Type: GrantFiled: September 29, 1999Date of Patent: January 29, 2002Assignee: Progenics Pharmaceuticals, Inc.Inventors: Graham P. Allaway, Paul J. Maddon
-
Publication number: 20010046512Abstract: This invention provides an antibody capable of specifically inhibiting the fusion of an HIV-1 envelope glycoprotein cell with an appropriate CD4+ cell without cross reacting with the HIV-1 envelope glycoprotein or CD4 and capable of inhibiting infection by one or more strains so HIV-1. This antibody is then used to identify a molecule which is important for HIV infection. Different uses of the antibody and the molecule are described.Type: ApplicationFiled: June 25, 2001Publication date: November 29, 2001Applicant: Progenics Pharmaceuticals, Inc.Inventors: Virginia M. Litwin, Graham P. Allaway, Paul J. Maddon
-
Patent number: 6261763Abstract: Previous studies of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein-mediated membrane fusion have focused on laboratory-adapted T-lymphotropic strains of the virus. The goal of this application was to develop a novel screening assay to characterize membrane fusion mediated by a primary HIV-1 isolate in comparison with a laboratory-adapted strain. To this end, a novel fusion assay was developed on the basis of the principle of resonance energy transfer, using HeLa cells stably transfected with gp120/gp41 from the T-lymphotropic isolate HIV-1LA1 or the macrophage-tropic primary isolate HIV-1JR-FL. These cells fused with CD4+ target cell lines with a tropism mirroring that of infection by the two viruses. Of particular note, HeLa cells expressing HIV-1JR-FL gp120/gp41 fused only with PM1 cells, a clonal derivative of HUT 78, and not with other T-cell or macrophage cell lines.Type: GrantFiled: March 16, 1998Date of Patent: July 17, 2001Assignee: Progenics Pharmaceuticals, Inc.Inventors: Graham P. Allaway, Virginia M. Litwin, Paul J. Maddon
-
Patent number: 6187748Abstract: This invention provides the CD4-IgG2 chimeric heterotetramer, wherein the heavy chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193). This invention also provides the CD4-IgG2 chimeric heterotetramer, wherein the light chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194). This invention also provides the CD4-IgG2 chimeric heterotetramer, wherein the heavy chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193) and the light chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194).Type: GrantFiled: June 7, 1995Date of Patent: February 13, 2001Assignee: Progenics Pharmaceuticals, Inc.Inventors: Paul J. Maddon, Gary A. Beaudry
-
Patent number: 6177549Abstract: This invention provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention also provides an immunoconjugate which comprises 1) a gamma radiation-emitting radionuclide of low to moderate cytotoxicity and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention further provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a heterotetramer comprising two heavy chains and two light chains, both heavy chains being either a) IgG2 heavy chains or b) chimeric CD4-IgG2 heavy chains, and both light chains being either a) kappa light chains or b) chimeric CD4-kappa light chains.Type: GrantFiled: June 10, 1999Date of Patent: January 23, 2001Assignee: Progenics Pharmaceuticals, Inc.Inventors: Paul J. Maddon, Graham P. Allaway
-
Patent number: 6107019Abstract: This invention provides methods for inhibiting fusion of HIV-1 to CD4.sup.+ cells which comprise contacting CD4.sup.+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4.sup.+ cells is inhibited. This invention also provides methods for inhibiting HIV-1 infection of CD4.sup.+ cells which comprise contacting CD4.sup.+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4.sup.+ cells is inhibited, thereby inhibiting the HIV-1 infection. This invention provides non-chemokine agents capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4.sup.+ cells. This invention also provides pharmaceutical compositions comprising an amount of the non-chemokine agent capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4.sup.+ cells effective to prevent fusion of HIV-1 to CD4.sup.Type: GrantFiled: June 13, 1997Date of Patent: August 22, 2000Assignee: Progenics Pharmaceuticals, Inc.Inventors: Graham P. Allaway, Virginia M. Litwin, Paul J. Maddon, William C. Olson
-
Patent number: 6093539Abstract: This invention provides an isolated single-stranded nucleic acid which encodes an aqueous-soluble polypeptide comprising at least a portion of a human T4 glycoprotein, which portion specifically forms a complex with a human immunodeficiency virus envelope glycoprotein.Type: GrantFiled: June 6, 1995Date of Patent: July 25, 2000Assignee: The Trustees of Columbia University in the City of New YorkInventors: Paul J. Maddon, Dan R. Littman, Leonard Chess, Richard Axel, Robin Weiss, J. Steven McDougal
-
Patent number: 6083478Abstract: An immunoconjugate which consists of a cytotoxic radionuclide and a homodimer comprising two heavy chains, the cytotoxic radionuclide being linked to the heavy chains dirctly or using a bifunctional chelator and a composition which comprises the immunoconjugate and an acceptable carrier.Type: GrantFiled: June 10, 1996Date of Patent: July 4, 2000Assignee: Progenics Pharmaceuticals, Inc.Inventors: Graham P. Allaway, Paul J. Maddon
-
Patent number: 6034223Abstract: This invention provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention also provides an immunoconjugate which comprises 1) a gamma radiation-emitting radionuclide of low to moderate cytotoxicity and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention further provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a heterotetramer comprising two heavy chains and two light chains, both heavy chains being either a) IgG2 heavy chains or b) chimeric CD4-IgG2 heavy chains, and both light chains being either a) kappa light chains or b) chimeric CD4-kappa light chains.Type: GrantFiled: June 7, 1995Date of Patent: March 7, 2000Assignee: Progenics Pharmaceuticals, Inc.Inventors: Paul J. Maddon, Graham P. Allaway
-
Patent number: 5958678Abstract: A single-stranded nucleic acid molecule which encodes an amino acid sequence comprising at least a portion of a T4 glycoprotein is provided. Additionally, amino acid sequences which comprise at least a portion of a T4 glycoprotein and are useful as a prophylaxis for treating a subject with acquired immune deficiency syndrome are provided. These amino acid sequences, which are capable of specifically forming a complex with a human immunodeficiency virus envelope glycoprotein and which are soluble in an aqueous solution may be administered to a subject infected with a human immunodeficiency virus so as to block the human immunodeficiency virus from binding to T4.sup.+ cells.Monoclonal antibodies directed to the water-soluble amino acid sequences of the present invention may be used as vaccines for immunizing a subject against acquired immune deficiency syndrome.Type: GrantFiled: December 12, 1994Date of Patent: September 28, 1999Assignee: The Trustees of Columbia University in the City of New YorkInventors: Paul J. Maddon, Dan R. Littman, Leonard Chess, Richard Axel, Robin Weiss, J. Steven McDougal
-
HIV-1 antigens, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
Patent number: 5886163Abstract: The subject invention provides a recombinant nucleic acid molecule which encodes a mutant HIV-1 gp120 envelope glycoprotein comprising a V3 loop deletion and a C4 domain.sub.(W.fwdarw.X) point mutation wherein X is an amino acid residue other than tryptophan, and the HIV-1 gp120 envelope glycoprotein encoded thereby.The subject invention further provides a method of obtaining partially purified antibodies which specifically bind to the CD4-binding domain of HIV-1 gp120 envelope glycoprotein, the partially purified antibodies produced thereby, and pharmaceutical compositions comprising same. Finally, the subject invention provides methods of treating HIV-1-infected subjects, and of reducing the likelihood of HIV-1-exposed and non-HIV-1-exposed subjects' becoming infected with HIV-1 using the pharmaceutical compositions of the subject invention.Type: GrantFiled: December 22, 1995Date of Patent: March 23, 1999Assignee: Progenics Pharmaceuticals, Inc.Inventors: Karl W. Hasel, Paul J. Maddon -
Patent number: 5871913Abstract: A single-stranded nucleic acid molecule which encodes the amino acid sequence comprising at least a portion of a T4 glycoprotein is provided. Additionally, amino acid sequences which comprise at least a portion of a T4 glycoprotein and are useful as a prophylaxis for treating a subject with acquired immune deficiency syndrome are provided. These amino acid sequences, which are capable of specifically forming a complex with a human immunodeficiency virus glycoprotein and which are soluble in an aqueous solution may be administered to a subject infected with a human immunodeficiency virus so as to block the human immunodeficiency virus from binding to T4 cells. Monoclonal antibodies directed to the water-soluble amino acid sequences of the present invention may be used as vaccines for immunizing a subject against acquired immune deficiency syndrome.Type: GrantFiled: June 5, 1995Date of Patent: February 16, 1999Assignee: The Trustees of Columbia University in the City of New YorkInventors: Paul J. Maddon, Dan R. Littman, Leonard Chess, Richard Axel, Robin Weiss, J. Steven McDougal
-
HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
Patent number: 5869624Abstract: The subject invention provides a recombinant nucleic acid molecule which encodes a mutant HIV-1 gp120 envelope glycoprotein comprising a V3 loop deletion and a C4 domain.sub.(W.fwdarw.X) point mutation wherein X is an amino acid residue other than tryptophan, and the HIV-1 gp120 envelope glycoprotein encoded thereby.The subject invention further provides a method of obtaining partially purified antibodies which specifically bind to the CD4-binding domain of HIV-1 gp120 envelope glycoprotein, the partially purified antibodies produced thereby, and pharmaceutical compositions comprising same. Finally, the subject invention provides methods of treating HIV-1-infected subjects, and of reducing the likelihood of HIV-1-exposed and non-HIV-1-exposed subjects' becoming infected with HIV-1 using the pharmaceutical compositions of the subject invention.Type: GrantFiled: March 26, 1993Date of Patent: February 9, 1999Assignee: Progenics Pharmaceuticals, Inc.Inventors: Karl W. Hasel, Paul J. Maddon -
Patent number: 5817767Abstract: The invention is directed to compositions containing CD4-based immunoconjugates and antibodies specific for the envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1). The CD4-based immunoconjugates comprise a portion obtained from CD4 conjugated to a heavy or light chain region obtained from IgG2. The CD4-immunoconjugates can be CD4-IgG2 chimeric heavy chain homodimers whose chains are encoded by the expression vector designated CD4-IgG2-pcDNA1 having ATCC Accession No. 40952, or heterotetramers having chimeric heavy chains encoded by the expression vector designated CD4-IgG2HC-pRcCMV having ATCC Accession No. 75193 and chimeric light chains encoded by the expression vector designated CD4-kLC-pRcCMV having ATCC Accession No. 75194. The compositions of the invention act synergistically to neutralize HIV-1.Type: GrantFiled: February 24, 1993Date of Patent: October 6, 1998Assignee: Progenics Pharmaceuticals, Inc.Inventors: Graham P. Allaway, Paul J. Maddon
-
Patent number: 5422274Abstract: This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +185.This invention also provides a method for treating a subject infected with a human immunodeficiency virus.Type: GrantFiled: February 5, 1992Date of Patent: June 6, 1995Assignees: The Trustees of Columbia University in the City of New York, SmithKline Beckman CorporationInventors: Paul J. Maddon, Richard Axel, Raymond W. Sweet, James Arthos
-
Patent number: 5126433Abstract: A single-stranded nucleic acid molecule which encodes an amino acid sequence comprising at least a portion of a T4 glycoprotein is provided. Additionally, amino acid sequences which comprise at least a portion of a T4 glycoprotein and are useful as a prophylaxis for treating a subject with acquired immune deficiency syndrome are provided. These amino acid sequences, are capable of specifically forming a complex with a human immunodeficiency virus envelope glycoprotein and which are soluble in an aqueous solution. Monoclonal antibodies directed to the water-soluble amino acid sequences of the present invention may be used as vaccines for immunizing a subject against acquired immune deficiency syndrome.Type: GrantFiled: October 23, 1987Date of Patent: June 30, 1992Assignee: The Trustees of Columbia University in the City of New YorkInventors: Paul J. Maddon, Leonard Chess, Richard Axel, Robin Weiss, Dan R. Littman, J. Steven McDougal
-
Patent number: 5110906Abstract: This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185.This invention also provides a method for treating a subject infected with a human immunodeficiency virus.Type: GrantFiled: February 24, 1988Date of Patent: May 5, 1992Assignees: The Trustees of Columbia University in the City of New York, Smithkline Beckman CorporationInventors: Paul J. Maddon, Richard Axel, Raymond W. Sweet, James Arthos